title: Gastric cancer management: Kinases as a target therapy.
abstract: The molecular diagnostics revolution has reshaped the practice of oncology by facilitating the identification of genetic, epigenetic and proteomic modifications correlated with cancer, thus delineating 'oncomaps' for various cancer types. These advances have enhanced our understanding of gastric cancer, one of the most fatal diseases worldwide, and culminated in the approval of novel molecular therapies such as trastuzumab. Gastric tumours display recurrent aberrations in key kinase oncogenes such as Her2, epidermal growth factor receptor (EGFR), PI3K, mTOR or c-Met, suggesting that these receptors are amenable to inhibition using specific drug agents. In this review, we examine the mutational landscape of gastric cancer, the use of kinase inhibitors as targeted therapies in gastric tumours and the clinical trials underway for novel inhibitors, highlighting successes, failures and future directions.
authors.affiliation: Department of Structural and Molecular Biology, University College London, London, UK.
authors.forename: Batoul
authors.initials: B
authors.lastname: Farran
authors.affiliation: Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Frankfurt am Main, DE, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Müller
authors.affiliation: Drug Research and Development Center, Federal University of Ceará, Fortaleza, CE, Brazil.
authors.forename: Raquel C
authors.identifier: http://orcid.org/0000-0002-3861-293X
authors.initials: RC
authors.lastname: Montenegro
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology
chemical_list: D047428:Protein Kinase Inhibitors; D011494:Protein Kinases
keywords: gastric cancer; kinases; monoclonal antibodies; precision medicine; small-molecule kinase inhibitors; targeted therapy